Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer

Table 2 Summary of the best responses to different post-osimertinib treatments

Variables		Chemotherapy	Chemotherapy+Anti-angiogenesis	Chemotherapy+Osimertinib	Chemotherapy+Immunotherapy	Osimertinib	Osimertinib+Anti-angiogenesis	Best support care	P
CR	-	-	-	-	-	-	-	-
PR	30	12	2	3	2	5	6	0
SD	66	26	11	2	6	15	4	2
PD	15	7	1	0	0	4	1	2
ORR(%)	27.0	26.7	14.3	60.0	25.0	20.8	54.5	0.0	<0.01
DCR(%)	86.5	84.4	92.9	100.0	100.0	83.3	90.9	50.0	<0.01

CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease,ORR Objective response rate, DCR Disease control rate

ISSN: 1741-7015